Evidence map›Paper›PMID 41531817›Full record

Observational studyPeerJ2026

A narrow therapeutic window of platelet P2Y

Liying Gong, Yaxin Liu, Jingle Li, Shiming Tan, Chengxian Guo, Zhengmei Wang, Huiling Song, Yun Kuang, Yu Cao, Guoping Yang

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Liying Gong *Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
Yaxin Liu *Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
Jingle LiDepartment of Cardiology, The Third Xiangya Hospital, Central South University, Changsh, China.
Shiming TanDepartment of the Clinical Hematology Laboratory, The Third Xiangya Hospital, Central South University, Changsha, China.
Chengxian GuoCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
Zhengmei WangCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
Huiling SongCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
Yun KuangCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
Yu CaoDepartment of Cardiology, The Third Xiangya Hospital, Central South University, Changsh, China.
Guoping YangCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Much evidence has been provided that a therapeutic window of P2Y Methods: In this observational study, we analyzed 860 high-risk patients who were undergoing PCI. The primary endpoint was the correlation between vasodilator-stimulated phosphoprotein platelet reactivity index (VASP-PRI) values with bleeding and ischemic components in high-risk patients. The secondary endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, urgent revascularization, and stroke at 12 months after the index procedure. Results: Among high-risk patients, VASP-PRI could significantly discriminate between PCI patients with and without ischemic events (area under the curve (AUC): 0.77; 95% CI [0.72-0.82]; Conclusion: Our results suggest that high-risk Chinese PCI patients have a narrow therapeutic window. Within this window, high-risk patients are at lower risk for both ischemic and bleeding events. Platelet reactivity may have significant implications for personalized antiplatelet therapy in high-risk patients.

Indexed as

Blood PlateletsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12AgedCell Adhesion MoleculesChinaEast Asian PeopleFemaleHemorrhageHumansMaleMicrofilament ProteinsMiddle AgedPhosphoproteinsCell Adhesion MoleculesMicrofilament ProteinsPhosphoproteinsPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Vasodilator-Stimulated PhosphoproteinDual antiplatelet therapyHigh-riskPercutaneous coronary interventionPlatelet reactivity

Identifiers

PMID41531817
PMCPMC12794635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.